CD99与ALK蛋白在间变性大细胞淋巴瘤患者中的复合表达及其临床意义  

Co-expression of CD99/MIC2 and ALK in anaplastic large-cell lymphoma tissues and its significance

作　　者：钟琳[1] 魏清柱[2] 黄学平[1] 季天海[1] 李锋[1] 王志强[1] 黎相照[1] 刘江欢[2] 赵彤[1] 

机构地区：[1]南方医科大学南方医院病理科,广州510515 [2]南方医科大学第三附属医院病理科

出　　处：《中华血液学杂志》2012年第3期173-176,共4页Chinese Journal of Hematology

基　　金：广东省科技计划项目（B30101）

摘　　要：目的探讨CD99／MIC2与间变性淋巴瘤激酶（anaplastic lymphoma kinase，ALK）蛋白在间变性大细胞淋巴瘤（anaplastic large cell lymphoma，ALCL）中的复合表达规律及其临床意义。方法对前期收集的25例有ALK蛋白表达和随访资料的ALCL患者进行回顾性分析，对ALK蛋白表达阳性组及阴性组患者生存时间进行比较；应用免疫组化S-P方法检测后期收集的25例ALCL患者病理组织标本和细胞株Karpas299细胞CD99蛋白和ALK蛋白表达，并进行两种蛋白复合表达分析。结果前期收集的25例ALCL患者中位生存期在ALK阳性组（17例）为59个月，阴性组（8例）为20个月，阳性组患者的预后优于阴性组（P〈0．05）。后期收集的25例ALCL患者标本中，CD99蛋白表达阳性18例（72．0％），阴性7例（28．0％）；ALK蛋白表达阳性19例（76．0％），阴性6例（24．0％）。在19例ALK阳性ALCL患者中16例（84．2％）CD99蛋白复合表达阳性，6例ALK阴性ALCL患者中，2例（33．3％）CD99蛋白复合表达阳性，两者差异有统计学意义（P〈0．05）。CD99和ALK蛋白在Karpas299细胞中呈弥漫阳性表达。结论CD99蛋白在ALCL患者中高表达，与ALK蛋白在ALCL患者中复合表达率较高，CD99联合ALK蛋白表达可作为ALCL病理诊断和判断预后的辅助指标，尤其对ALK蛋白表达阳性的ALCL患者更具有临床意义。Objective To investigate co-expression of CD99/MIC2 and anaplastic lymphoma kinase （ALK） protein in anaplastic large-cell lymphoma （ALCL） tissues and Karpas 299 cells and its significance. Methods Clinical prognoses and ALK protein expressions of 25 cases of ALCL were reviewed retrospectively, the median duration of survival was analyzed for patients with ALK ＋ ALCL and ALK - ALCL. Histological and immunohistochemical staining were applied to other 25 cases of ALCL and paraffin-embedded tissue from human anaplastic large-cell lymphoma Karpas 299 cells to detect the protein of CD99 and ALK. Results Of former 25 cases of ALCL, median duration of survival for ALK ＋ patients was 59 months, whereas 20 months for ALK patients. The prognosis of ALK ＋ group was better than that of ALK- group, survival curves of these two groups showed statistically significant （P 〈 0.05 ）. CD99 was positive in 18 cases （72.0%） while negative in 7 cases （28.0%） of the latter 25 ALCL, ALK was positive in 19 cases （76.0%） while negative in 6 cases （24.0%） ; Of 19 ALK＋ ALCL, 16 （84.2%） cases co-expressed CD99-ALK; and in 6 ALK- ALCL, 2（ 33.3% ） were CD99-ALK double negative, the expression of CD99 protein strongly correlated with that of ALK protein （ P 〈 0.05 ）. ALK and CD99 protein expressed in Karpas 299 cells with diffuse distribution. Conclusions CD99 highly expressed in ALCL, and showed high rate of co-expression with ALK. CD99 protein expression could be considered as a helpful diagnostic and prognostic factor of ALCL, especially for ALK ＋ALCL.

关 键 词：淋巴瘤 T细胞 抗原 CD99 间变性淋巴瘤激酶 免疫组织化学 预后 

分 类 号：R733.1[医药卫生—肿瘤]